Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Kempharm Inc
(NQ:
KMPH
)
9.810
USD
+1.100 (+12.63%)
Streaming Delayed Price
Updated: 2:23 PM EST, Feb 26, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Kempharm Inc
< Previous
1
2
3
4
5
6
Next >
Thinking about buying stock in Salarius Pharmaceuticals, KemPharm, Ocular Therapeutix, Boxlight Corp, or Endra Life Sciences?
February 16, 2021
InvestorsObserver issues critical PriceWatch Alerts for SLRX, KMPH, OCUL, BOXL, and NDRA.
From
PR Newswire
InvestorNewsBreaks – KemPharm Inc. (NASDAQ: KMPH) Secures $52.4M in Follow-on and $44M in Warrant Exchange Transaction
February 12, 2021
From
InvestorBrandNetwork
KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
January 27, 2021
From
GlobeNewswire News Releases
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
January 14, 2021
From
GlobeNewswire News Releases
KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
January 13, 2021
From
GlobeNewswire News Releases
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
January 08, 2021
From
GlobeNewswire News Releases
KemPharm Announces 1-for-16 Reverse Stock Split
December 23, 2020
From
GlobeNewswire News Releases
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
December 22, 2020
From
GlobeNewswire News Releases
KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
December 02, 2020
From
GlobeNewswire News Releases
REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
November 30, 2020
From
GlobeNewswire News Releases
KemPharm Provides Update on Development Pipeline
November 23, 2020
From
GlobeNewswire News Releases
KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
November 18, 2020
From
GlobeNewswire News Releases
KemPharm Reports Third Quarter 2020 Financial Results
October 29, 2020
From
GlobeNewswire News Releases
KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
October 26, 2020
From
GlobeNewswire News Releases
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
October 22, 2020
From
GlobeNewswire News Releases
KemPharm and Corium Expand Relationship with New Consultation Services Agreement
October 05, 2020
From
GlobeNewswire News Releases
KemPharm Files Preliminary Proxy for Special Meeting of Stockholders
September 25, 2020
From
GlobeNewswire News Releases
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
September 21, 2020
Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentations
From
GlobeNewswire News Releases
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing
September 21, 2020
Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentations
From
GlobeNewswire News Releases
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
September 14, 2020
From
GlobeNewswire News Releases
Virtual Conference for Life Sciences Companies Broadcast Live September 17th, 2020
September 14, 2020
From
GlobeNewswire News Releases
KemPharm’s Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies
September 10, 2020
From
GlobeNewswire News Releases
KemPharm to Present at Upcoming September Investor Conferences
September 02, 2020
Presentations to Highlight Corporate, Regulatory and Pipeline Advancements
From
GlobeNewswire News Releases
KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA
August 14, 2020
From
GlobeNewswire News Releases
KemPharm Reports Second Quarter 2020 Financial Results
August 12, 2020
From
GlobeNewswire News Releases
KemPharm to Report Second Quarter 2020 Financial Results
August 04, 2020
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, August 12, 2020, 4:30 p.m. ET
From
GlobeNewswire News Releases
KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484
July 28, 2020
From
GlobeNewswire News Releases
KemPharm Issues Letter to Shareholders
June 18, 2020
From
GlobeNewswire News Releases
KemPharm Receives Day-74 Letter for KP415 NDA
May 19, 2020
From
GlobeNewswire News Releases
KemPharm Reports First Quarter 2020 Financial Results
May 12, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.